Trials / Completed
CompletedNCT01200225
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Prospective Observational Study to Asses the Insulin Resistance (IR) and Its Impact on Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegasys and Copegus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,155 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus. Data will be collected from each patient during the up to 72 weeks of treatment and for 24 weeks of treatment-free follow-up.
Conditions
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2010-09-13
- Last updated
- 2016-11-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01200225. Inclusion in this directory is not an endorsement.